Corrigendum to “The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression” [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532, (S0165032724020494), (10.1016/j.jad.2024.12.061)]

The authors wish to express regret regarding an error in the publication of the original article. Fig. 2 of the published manuscript included scatter and density plots showing the relationship between Week 3 change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score and the Five-Dimensional Altered States of Consciousness (5D-ASC) Oceanic Boundlessness dimension and Emotional Breakthrough Inventory (EBI) only, but omitted the Anxious Ego Dissolution 5D-ASC dimension which was also referred to in the manuscript text. A corrected Fig. 2 is included in this corrigendum which illustrates all three measures. The linear regression lines show a similar overall relationship between drug effect and outcome at the different doses in the Oceanic Boundlessness and EBI plots. For the Anxious Ego Dissolution plot, there is no relationship.[Figure presented] Fig. 2. Scatter and Density Plot of 5D-ASC: Oceanic Boundlessness, EBI, and Anxious Ego Dissolution Scores Plotted Against MADRS Change from Baseline to Week 3. The densities along the axes are the kernel density estimates. The lines represent linear regression lines of best fit, with the green shading representing the 95 % confidence interval of the regression line. Abbreviations: 5D-ASC: Five-Dimensional Altered States of Consciousness; EBI: Emotional Breakthrough Inventory; MADRS: Montgomery-Åsberg Depression Rating Scale; rho: Pearson's correlation coefficient. The authors would like to apologise for any inconvenience caused.